M
Michal Bista
Researcher at AstraZeneca
Publications - 24
Citations - 2980
Michal Bista is an academic researcher from AstraZeneca. The author has contributed to research in topics: Protease & Gene. The author has an hindex of 15, co-authored 23 publications receiving 2586 citations. Previous affiliations of Michal Bista include Max Planck Society & Laboratory of Molecular Biology.
Papers
More filters
Journal ArticleDOI
Lifeact: a versatile marker to visualize F-actin
Julia Riedl,Alvaro H. Crevenna,Kai Kessenbrock,Jerry Haochen Yu,Dorothee Neukirchen,Michal Bista,Frank Bradke,Dieter E. Jenne,Tad A. Holak,Zena Werb,Michael Sixt,Roland Wedlich-Söldner +11 more
TL;DR: Lifeact, a 17-amino-acid peptide, is described, which stained filamentous actin (F-actin) structures in eukaryotic cells and tissues and in its chemically modified peptide form allowed visualization of actin dynamics in nontransfectable cells.
Journal ArticleDOI
Robust Generation of Lead Compounds for Protein-Protein Interactions by Computational and MCR Chemistry: p53/Hdm2 Antagonists
Journal ArticleDOI
Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival
Jason Grant Kettle,Husam Alwan,Michal Bista,Jason Breed,Nichola L. Davies,Kay Eckersley,Shaun M. Fillery,Kevin Michael Foote,Louise Goodwin,D.R Jones,Helena Käck,Alan Lau,Johannes Wilhelmus Maria Nissink,Jon Read,James S. Scott,Benjamin Taylor,Graeme Walker,Lisa Wissler,Marta Wylot +18 more
TL;DR: It is concluded that the role of MTH1 in carcinogenesis and utility of its inhibition is yet to be established and the difference between the responses of the highly selective inhibitors and published tool compounds suggests that the effect reported for the latter may be due to off-target cytotoxic effects.
Journal ArticleDOI
Enabling Large-Scale Design, Synthesis and Validation of Small Molecule Protein-Protein Antagonists
David Ryan Koes,Kareem Khoury,Yijun Huang,Wei Wang,Michal Bista,Grzegorz M. Popowicz,Siglinde Wolf,Tad A. Holak,Alexander Dömling,Carlos J. Camacho +9 more
TL;DR: A novel pharmacophore-based interactive screening technology that builds on the role anchor residues, or deeply buried hot spots, have in PPIs, and redesigns these entry points with anchor-biased virtual multicomponent reactions, delivering tens of millions of readily synthesizable novel compounds.
Journal ArticleDOI
1,4-Thienodiazepine-2,5-diones via MCR (I): Synthesis, Virtual Space and p53-Mdm2 Activity
Yijun Huang,Siglinde Wolf,Michal Bista,Lidio Meireles,Carlos J. Camacho,Tad A. Holak,Alexander Dömling +6 more
TL;DR: 1,4‐Thienodiazepine‐2,5‐diones have been synthesized via the Ugi‐Deprotection‐Cyclization (UDC) approach starting from Gewald 2‐aminothiophenes in a convergent and versatile manner and some compounds exhibited promising antagonistic activity.